- Home
- VIR vs GENI Comparison
VIR vs GENI Comparison
Compare VIR & GENI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VIR | GENI |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VIR | GENI |
|---|---|---|
| Price | $8.40 | $4.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | ★ $19.63 | $13.19 |
| AVG Volume (30 Days) | 3.5M | ★ 6.3M |
| Earning Date | 05-06-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,556,000.00 | N/A |
| Revenue This Year | N/A | $31.59 |
| Revenue Next Year | $1,049.62 | $28.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.16 | $4.40 |
| 52 Week High | $10.91 | $13.73 |
Technical Indicators
Market Signals| Indicator | VIR | GENI |
|---|---|---|
| Relative Strength Index (RSI) | 45.05 | 26.63 |
| Support Level | $5.14 | N/A |
| Resistance Level | $10.29 | $11.60 |
| Average True Range (ATR) | 0.47 | 0.28 |
| MACD | -0.18 | 0.02 |
| Stochastic Oscillator | 3.20 | 9.77 |
Price Performance
Historical ComparisonAbout VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
About GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.